Feeds

Final drug trial victim out of the woods

As placebo man balks at follow-ups

The smart choice: opportunity from uncertainty

All of the volunteers given an experimental immune drug in a London trial have now made it off the critical list at Northwick Park hospital.

The last of six men given biotech firm TeGenero's TGN1412 compound is now fully conscious and looks set to make a full recovery.

Intensive care clinical director Dr Ganesh Suntharalingam said: "We are delighted that the six patients have come through safely from the most critical stage of their condition."

He praised intensive care staff for how they dealt with the victims' very serious condition when they were transferred there from a private testing unit more than three weeks ago.

TeGenero said today its preliminary investigations showed it had followed all correct procedures in the animal testing phase of the drug. It also says the problem was unforseeable based on preclinical results (see here for why many think the problems might have been foreseeable though).

Watchdog the Medicines and Healthcare products Regulatory Agency (MHRA) agreed, saying it hasn't been able find a problem with how the trial was carried out.

It also couldn't find evidence of contamination of the drug. Some had speculated bacterial toxins might be responsible for the multiple organ failure.

MRHA added that its findings are not yet conclusive, but that the suspected flaws in the action of the drug itself were the most likely cause. The Secretary of State for Health is assembling a panel of experts to investigate why the animal trials didn't pick up the near-deadly complications.

Meanwhile, Raste Khan, 23, one of the men given a harmless placebo, appeared in The Sun today, saying he was still traumatised by what he saw during the trials. "I still feel haunted by it and I know my family have been extremely upset. I am too frightened even to get sleeping pills from the doctor."

He claims test contractor Parexel is demanding he honour the terms of his contract by attending follow-ups in order to pocket his £2,000 volunteer fee.

Testing contractor Parexel was unavailable for comment. ®

The Power of One Infographic

More from The Register

next story
World Solar Challenge contender claims new speed record
One charge sees Sunswift travel 500kms at over 100 km/h
SMELL YOU LATER, LOSERS – Dumbo tells rats, dogs... humans
Junk in the trunk? That's what people have
The Sun took a day off last week and made NO sunspots
Someone needs to get that lazy star cooking again before things get cold around here
Boffins discuss AI space program at hush-hush IARPA confab
IBM, MIT, plenty of others invited to fill Uncle Sam's spy toolchest, but where's Google?
Bad back? Show some spine and stop popping paracetamol
Study finds common pain-killer doesn't reduce pain or shorten recovery
Forty-five years ago: FOOTPRINTS FOUND ON MOON
NASA won't be back any time soon, sadly
Jurassic squawk: Dinos were Earth's early FEATHERED friends
Boffins research: Ancient dinos may all have had 'potential' fluff
prev story

Whitepapers

Top three mobile application threats
Prevent sensitive data leakage over insecure channels or stolen mobile devices.
Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Boost IT visibility and business value
How building a great service catalog relieves pressure points and demonstrates the value of IT service management.
Designing a Defense for Mobile Applications
Learn about the various considerations for defending mobile applications - from the application architecture itself to the myriad testing technologies.
Build a business case: developing custom apps
Learn how to maximize the value of custom applications by accelerating and simplifying their development.